<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771481</url>
  </required_header>
  <id_info>
    <org_study_id>RP021</org_study_id>
    <nct_id>NCT04771481</nct_id>
  </id_info>
  <brief_title>Metoclopramide for Acute Upper GI Bleeding</brief_title>
  <official_title>The Efficacy of Metoclopramide for Gastric Visualization by Endoscopy in Patients With Acute Upper Gastrointestinal Bleeding: Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Chulalongkorn Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of blood clot in stomach limited quality of endoscopic view ,which affect&#xD;
      successful rate of hemostatic endoscopy in patient with acute upper gastrointestinal&#xD;
      bleeding. The study is aimed to evaluate the efficacy of metoclopramide, as pro-kinetic agent&#xD;
      ,for gastric visualization in the patient with acute UGIB; double-blind randomized controlled&#xD;
      trial and two centers study. The patient were randomly assigned to receive either&#xD;
      metoclopramide (10mg) intravenously or placebo before endoscopy 30-120 min. The primary&#xD;
      endpoint was endoscopic yield, assessed by objective gastric visualized scoring systems.&#xD;
      Secondary end points include duration of endoscope, technical success rate, the need for&#xD;
      second-look EGD, units of blood transfusion, length of hospital stay and 30-day rebleeding&#xD;
      rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the efficacy of metoclopramide for gastric visualization by endoscopy in patients with acute upper gastrointestinal bleeding</measure>
    <time_frame>up to 2 hour</time_frame>
    <description>assess by objective gastric visualised scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of endoscopy</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>duration of endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>units of red cell transfusion</measure>
    <time_frame>up to 30 days</time_frame>
    <description>units of red cell transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the need of second-look EGD</measure>
    <time_frame>72 hours and 30days after index EGD</time_frame>
    <description>the need of second-look EGD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>up to 30days</time_frame>
    <description>length of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Acute Upper Gastrointestinal Bleeding</condition>
  <condition>Effect of Drug</condition>
  <arm_group>
    <arm_group_label>metoclopramide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metoclopramide 10mg with normal saline up to 10 ml IV slowly push in 5minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 10 ml IV slowly push in 5 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>metoclopramide 10 mg intravenous form</description>
    <arm_group_label>metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 10 mL Injection</intervention_name>
    <description>Normal saline 10 ml intravenous form</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 18 years&#xD;
&#xD;
          2. Active upper GI bleeding ( defined as fresh or bright red hematemesis within 24hr. or&#xD;
             presented of blood via NG aspiration )&#xD;
&#xD;
          3. Underwent upper GI endoscopy within 12hr&#xD;
&#xD;
          4. Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy of metoclopramide&#xD;
&#xD;
          2. History of gastric or duodenal surgery&#xD;
&#xD;
          3. Known case esophageal, gastric or duodenal cancer&#xD;
&#xD;
          4. Diagnosed with advanced HIV infection (defined as CD4 cell count &lt;200 cells/mm3 or WHO&#xD;
             clinical stage 3 or 4)&#xD;
&#xD;
          5. Poor ambulatory status (defined as capable of only limited selfcare, confined to bed&#xD;
             or chair more than 50% of waking hours; applied from WHO/ECOG performance stage â‰¥3)&#xD;
&#xD;
          6. Pregnancy or lactating&#xD;
&#xD;
          7. NG lavage was done with solution &gt; 50 ml.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rapat Pittayanon, MD, MSc</last_name>
    <phone>+6622564356</phone>
    <email>Rapat.P@chula.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thanrada Vimonsuntirungsri, MD</last_name>
    <phone>+66853356240</phone>
    <email>aa_choc@docchula.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <state>Pathumwan</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Chonlada</last_name>
      <phone>+6622564356</phone>
      <email>chonlada.pha@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Chulalongkorn Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Rapat Pittayanon</investigator_full_name>
    <investigator_title>MD, MSc (Medicine and Experimental Surgery) Associate Professor, Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University Secretary General, the Gastroenterological Association of Thailand (GAT)</investigator_title>
  </responsible_party>
  <keyword>Metoclopramide</keyword>
  <keyword>Acute upper gastrointestinal bleeding</keyword>
  <keyword>Gastric visualization</keyword>
  <keyword>Endoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

